CA2918487C - Azaindole compounds, synthesis thereof, and methods of using the same - Google Patents

Azaindole compounds, synthesis thereof, and methods of using the same Download PDF

Info

Publication number
CA2918487C
CA2918487C CA2918487A CA2918487A CA2918487C CA 2918487 C CA2918487 C CA 2918487C CA 2918487 A CA2918487 A CA 2918487A CA 2918487 A CA2918487 A CA 2918487A CA 2918487 C CA2918487 C CA 2918487C
Authority
CA
Canada
Prior art keywords
methyl
hydrogen
compound
mmol
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2918487A
Other languages
English (en)
French (fr)
Other versions
CA2918487A1 (en
Inventor
Pravin S. Shirude
Maruti N. Naik
Vikas Narayan Shinde
Shahul Hameed Peer Mohamed
Monalisa Chatterji
Radha K. Shandil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FOUNDATION FOR NEGLECTED DISEASE RESEARCH
TB Alliance
Original Assignee
FOUNDATION FOR NEGLECTED DISEASE RESEARCH
TB Alliance
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FOUNDATION FOR NEGLECTED DISEASE RESEARCH, TB Alliance filed Critical FOUNDATION FOR NEGLECTED DISEASE RESEARCH
Publication of CA2918487A1 publication Critical patent/CA2918487A1/en
Application granted granted Critical
Publication of CA2918487C publication Critical patent/CA2918487C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2918487A 2013-07-17 2014-07-10 Azaindole compounds, synthesis thereof, and methods of using the same Active CA2918487C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3196CH2013 2013-07-17
IN3196/CHE/2013 2013-07-17
PCT/US2014/046100 WO2015009525A1 (en) 2013-07-17 2014-07-10 Azaindole compounds, synthesis thereof, and methods of using the same

Publications (2)

Publication Number Publication Date
CA2918487A1 CA2918487A1 (en) 2015-01-22
CA2918487C true CA2918487C (en) 2021-08-03

Family

ID=51261257

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2918487A Active CA2918487C (en) 2013-07-17 2014-07-10 Azaindole compounds, synthesis thereof, and methods of using the same

Country Status (10)

Country Link
US (1) US9163020B2 (enExample)
EP (1) EP3021947B1 (enExample)
JP (1) JP6366709B2 (enExample)
KR (1) KR102301753B1 (enExample)
CN (1) CN105636646B (enExample)
AU (1) AU2014290598B2 (enExample)
CA (1) CA2918487C (enExample)
EA (1) EA028611B1 (enExample)
ES (1) ES2644025T3 (enExample)
WO (1) WO2015009525A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201512197A (zh) * 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
GB201317363D0 (en) * 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
CN111629721A (zh) 2017-12-06 2020-09-04 百乐吉公司 用于减少过敏反应的组合物和方法
RU2702224C2 (ru) * 2018-03-29 2019-10-07 Общество С Ограниченной Ответственностью "Мт-Медикалс" Производные фенил формамидина, обладающие антимикобактериальной активностью
CN112543757A (zh) * 2018-06-15 2021-03-23 卡迪拉保健有限公司 对结核菌具有抗菌活性的缩合氮杂杂芳基化合物
WO2020188405A1 (en) * 2019-03-20 2020-09-24 Foundation For Neglected Disease Research Benzimidazoles derivatives as anti-tuberculosis agents
CN111393435A (zh) * 2020-03-16 2020-07-10 青岛吉澳医药科技有限公司 氮杂吲哚酰胺类化合物及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1532980A1 (en) * 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
EP2185560A4 (en) * 2007-08-10 2011-10-05 Lundbeck & Co As H HETEROARYLAMIDE ANALOGS
RU2576662C2 (ru) * 2010-03-18 2016-03-10 Энститю Пастер Корея Противоинфекционные соединения

Also Published As

Publication number Publication date
CA2918487A1 (en) 2015-01-22
CN105636646A (zh) 2016-06-01
WO2015009525A1 (en) 2015-01-22
AU2014290598B2 (en) 2018-11-08
JP6366709B2 (ja) 2018-08-01
AU2014290598A1 (en) 2016-02-11
US9163020B2 (en) 2015-10-20
EA201690227A1 (ru) 2016-07-29
EA028611B1 (ru) 2017-12-29
KR102301753B1 (ko) 2021-09-15
JP2016530242A (ja) 2016-09-29
CN105636646B (zh) 2017-12-19
EP3021947B1 (en) 2017-08-23
KR20160058757A (ko) 2016-05-25
EP3021947A1 (en) 2016-05-25
ES2644025T3 (es) 2017-11-27
BR112016000712A2 (pt) 2022-03-22
US20150025087A1 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
EP3021947B1 (en) Azaindole compounds, synthesis thereof, and methods of using the same
US11952380B2 (en) Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors
US12180198B2 (en) Ribocil C antibiotics effective for Gram-negative pathogens
US10822339B2 (en) Pyrrolopyrimidine five-membered azacyclic derivative and application thereof
KR102595730B1 (ko) 새로운 구충 퀴놀린-3-카르복스아미드 유도체
US20230167114A1 (en) Macrocyclic jak inhibitor and use thereof
US20200289514A1 (en) Novel Pyrazolo Pyrimidine Derivatives
US9255107B2 (en) Heteroaryl alkyne compound and use thereof
EP4233834A2 (en) Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks
US12544374B2 (en) AZA-quinoline compounds and uses thereof
US12479850B2 (en) Compound having Axl and c-Met kinase inhibitory activity, preparation thereof and application thereof
US20100261714A1 (en) Inhibitors of hiv replication
CN112409373A (zh) 作为抗癌剂的取代的[5,6]环-4(3h)-嘧啶酮
US20250127780A1 (en) Imidazo[4,5-b]pyridine and pyrazolo[1,5-a]pyrimidine derivatives as sik modulators for the treatment of rheumatoid arthritis
JP2025511975A (ja) Ｃｄｋ９阻害剤
US10385056B2 (en) 4-substituted pyrrolo[2,3-d]pyrimidine compound and use thereof
US20210292333A1 (en) Condensed azaheteroaryl compounds having antibacterial activity against tuberculosis bacteria
JP2021504489A (ja) 抗菌複素環式化合物及びそれらの合成
CZ309884B6 (cs) Substituovaný purin, jeho použití a farmaceutický přípravek ho obsahující
BR112016000712B1 (pt) Compostos de azaindol, síntese dos mesmos e métodos de uso dos mesmos
Tshinavhe Design, synthesis and anti-Tb evaluation of 6 dialkylaminopyrimidine carboxamides
CN111393435A (zh) 氮杂吲哚酰胺类化合物及其制备方法和用途
Rukweza Quinolone-Pyrazinamide Derivatives: Synthesis, characterisation, in silico ADME analysis and in vitro biological evaluation against Mycobacterium tuberculosis.
Venditti Antimycobacterial compounds targeting MmpL3 and tryptophan biosynthetic pathway

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190708

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240708

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241023

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241023

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250625

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250625

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260602

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260603